European Journal of Heart Failure · 2019 · 73 citations · 27 references
MedicineCardiologyInternal MedicineCardio-oncologyClinical CardiologySurvival AnalysisCancer MortalityCardiovascular DiseaseHeart FailureMortality ModelingMortality PatternsSudden Cardiac Death PreventionCancer Mortality ForecastingCancer Mortality ModelingHeart Failure EpidemiologySudden Death PreventionTemporal Trends In Mortality
AIMS: Better management of heart failure (HF) over the past two decades has improved survival, mainly by reducing the incidence of death due to cardiovascular (CV) causes. Deaths due to non-CV causes, particularly cancer, may be increasing. This study explored the modes of death of consecutive patients who attended a HF clinic over 17 years. METHODS AND RESULTS: A total of 935 deaths were ascertained from 2002 to 2018 among 1876 patients (mean age 65.8 ± 12.5 years, 75% men, left ventricular ejection fraction < 50%) admitted to our HF clinic. Median follow-up was 4.2 years [1.9-7.8]. Mode of death was curated from patient health records and verified by the Catalan and Spanish health system databases. Trends for every mode of death were assessed by polynomial regression. Two trends were observed: a significant reduction in sudden death (P = 0.03) without changes in HF progression as mode of death (P = 0.26), and a significant increase in non-CV modes of death (P < 0.001). Non-CV deaths accounted for 17.4% of deaths in 2002 and 65.8% of deaths in 2018. A total 138 deaths were due to cancer (37% of non-CV deaths). A significant trend was observed towards a progressive increase in cancer deaths over time (P = 0.002). The main mode of cancer mortality was lung cancer. CONCLUSIONS: The modes of death in HF have shifted over the last two decades. Patients with HF die less due to sudden death and more due to non-CV causes, mainly cancer. Whether HF triggers cancer, or cancer develops in HF survivors, deserves further insight.
27
John G.F. Cleland, Andrew J.S. Coats, Ewa A. Jankowska et al. · PubMed · 2021 · 19.5K citations
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
John J.V. McMurray, Stamatis Adamopoulos, Stefan D. Anker et al. · European Heart Journal · 2012 · 6.9K citations · Full text
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
John J.V. McMurray, Milton Packer, Akshay S. Desai et al. · New England Journal of Medicine · 2014 · 6.8K citations · Full text
Medicine, Cardiology, Pharmacology +11